Anti-galactocerebroside antibodies in human cerebrospinal fluids determined by enzyme-linked immunosorbent assay (ELISA). 1988

T Ichioka, and K Uobe, and M Stoskopf, and Y Kishimoto, and G Tennekoon, and W W Tourtellotte
Kennedy Institute, School of Medicine, Johns Hopkins University, Baltimore, Maryland 21205.

The standard ELISA technique was improved for the detection of antigalactocerebroside antibody in biological fluid. Mouse monoclonal antigalactocerebroside antibody was used to demonstrate specificity and sensitivity of the technique. After optimization of the assay, the usefulness of this measurement for the evaluation of patients with multiple sclerosis was assessed. The presence of antigalactocerebroside antibodies in the cerebrospinal fluid of 20 patients with multiple sclerosis, 10 with other neurological diseases and 10 normal individuals was determined. All the CSF samples from normal individuals were negative. In patients with multiple sclerosis 14 of the 20 samples had elevated levels of antigalactocerebroside antibody, whereas with other neurological diseases 5 out of 10 were positive. Antigalactocerebroside levels were lower in samples from patients during an acute relapse than in those from more chronic cases. These results indicate that the presence of antigalactocerebroside antibody in cerebrospinal fluid is not specific to MS but may reflect previous damage to myelin.

UI MeSH Term Description Entries
D007142 Immunoglobulin gamma-Chains Heavy chains of IMMUNOGLOBULIN G having a molecular weight of approximately 51 kDa. They contain about 450 amino acid residues arranged in four domains and an oligosaccharide component covalently bound to the Fc fragment constant region. The gamma heavy chain subclasses (for example, gamma 1, gamma 2a, and gamma 2b) of the IMMUNOGLOBULIN G isotype subclasses (IgG1, IgG2A, and IgG2B) resemble each other more closely than the heavy chains of the other IMMUNOGLOBULIN ISOTYPES. Immunoglobulins, gamma-Chain,Immunoglobulin gamma-Chain,gamma Immunoglobulin Heavy Chain,gamma Immunoglobulin Heavy Chains,gamma-1-Immunoglobulin Heavy Chain,gamma-2a-Immunoglobulin Heavy Chain,gamma-2b-Immunoglobulin Heavy Chain,gamma-Chain Immunoglobulins,Heavy Chain, gamma-1-Immunoglobulin,Heavy Chain, gamma-2a-Immunoglobulin,Heavy Chain, gamma-2b-Immunoglobulin,Immunoglobulin gamma Chain,Immunoglobulin gamma Chains,Immunoglobulins, gamma Chain,gamma 1 Immunoglobulin Heavy Chain,gamma 2a Immunoglobulin Heavy Chain,gamma 2b Immunoglobulin Heavy Chain,gamma Chain Immunoglobulins,gamma-Chain, Immunoglobulin,gamma-Chains, Immunoglobulin
D009103 Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903) MS (Multiple Sclerosis),Multiple Sclerosis, Acute Fulminating,Sclerosis, Disseminated,Disseminated Sclerosis,Sclerosis, Multiple
D001927 Brain Diseases Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM. Intracranial Central Nervous System Disorders,Brain Disorders,CNS Disorders, Intracranial,Central Nervous System Disorders, Intracranial,Central Nervous System Intracranial Disorders,Encephalon Diseases,Encephalopathy,Intracranial CNS Disorders,Brain Disease,Brain Disorder,CNS Disorder, Intracranial,Encephalon Disease,Encephalopathies,Intracranial CNS Disorder
D002554 Cerebrosides Neutral glycosphingolipids that contain a monosaccharide, normally glucose or galactose, in 1-ortho-beta-glycosidic linkage with the primary alcohol of an N-acyl sphingoid (ceramide). In plants the monosaccharide is normally glucose and the sphingoid usually phytosphingosine. In animals, the monosaccharide is usually galactose, though this may vary with the tissue and the sphingoid is usually sphingosine or dihydrosphingosine. (From Oxford Dictionary of Biochemistry and Molecular Biology, 1st ed)
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005699 Galactosylceramides Cerebrosides which contain as their polar head group a galactose moiety bound in glycosidic linkage to the hydroxyl group of ceramide. Their accumulation in tissue, due to a defect in beta-galactosidase, is the cause of galactosylceramide lipidosis or globoid cell leukodystrophy. Galactocerebrosides,Galactosyl Ceramide,Galactosyl Ceramides,Galactosylceramide,Ceramide, Galactosyl,Ceramides, Galactosyl
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D001323 Autoantibodies Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them. Autoantibody

Related Publications

T Ichioka, and K Uobe, and M Stoskopf, and Y Kishimoto, and G Tennekoon, and W W Tourtellotte
January 1988, Allergie und Immunologie,
T Ichioka, and K Uobe, and M Stoskopf, and Y Kishimoto, and G Tennekoon, and W W Tourtellotte
January 1983, Diagnostic immunology,
T Ichioka, and K Uobe, and M Stoskopf, and Y Kishimoto, and G Tennekoon, and W W Tourtellotte
January 1985, Transactions of the Royal Society of Tropical Medicine and Hygiene,
T Ichioka, and K Uobe, and M Stoskopf, and Y Kishimoto, and G Tennekoon, and W W Tourtellotte
January 1980, Journal of medical virology,
T Ichioka, and K Uobe, and M Stoskopf, and Y Kishimoto, and G Tennekoon, and W W Tourtellotte
March 1999, Contemporary topics in laboratory animal science,
T Ichioka, and K Uobe, and M Stoskopf, and Y Kishimoto, and G Tennekoon, and W W Tourtellotte
January 1994, Methods in molecular biology (Clifton, N.J.),
T Ichioka, and K Uobe, and M Stoskopf, and Y Kishimoto, and G Tennekoon, and W W Tourtellotte
December 1978, Hospital practice,
T Ichioka, and K Uobe, and M Stoskopf, and Y Kishimoto, and G Tennekoon, and W W Tourtellotte
January 2017, Methods in molecular biology (Clifton, N.J.),
T Ichioka, and K Uobe, and M Stoskopf, and Y Kishimoto, and G Tennekoon, and W W Tourtellotte
January 2022, Methods in molecular biology (Clifton, N.J.),
T Ichioka, and K Uobe, and M Stoskopf, and Y Kishimoto, and G Tennekoon, and W W Tourtellotte
January 1981, Journal of medical virology,
Copied contents to your clipboard!